4
BPC-157, NAD+, PT-141 and GHK-Cu compared
Comfortable movement, energy, desire and skin appearance sound close together in conversation. Their research histories lead to very different places.
Everyday aims compared
| Everyday aim | Research to start with | What remains open |
|---|---|---|
| Comfortable movement after injury | BPC-157’s 2025 review found only three small human pilots alongside a large animal literature. | Whether human injuries heal better, and the long-term safety profile. |
| Physical function and energy | Oral NMN in middle-aged adults improved walking distance and reported wellbeing as blood NAD+ rose. | How consistently the functional finding repeats and whether larger health benefits follow. |
| Desire that has been lost | Bremelanotide’s two Phase 3 trials improved desire and reduced distress in premenopausal women with HSDD. | Benefits for other people and other sexual concerns. |
| Skin or hair appearance | Small topical GHK-Cu studies and a GHK-containing hair combination found particular changes. | The size and reliability of cosmetic benefit across preparations, and human evidence for systemic use. |
The walking finding gets my first request for a repeat. It connects an accessible activity with a measurable result, and leaves plenty of room for confirmation or disappointment.
Different product categories
BPC-157 has no approved medical use anywhere. NAD+ and its precursors appear in supplements, while NMN’s supplement status has been contested by FDA. Compounded NAD+ injections have no FDA drug approval. GHK-Cu is a legal cosmetic ingredient; systemic uses remain unapproved.
Bremelanotide has a defined US prescription indication for acquired, generalised HSDD in premenopausal women. Its approval covers a particular product, population and use. The same chemical name on research material conveys no equivalent quality assurance.
This is where broad talk about “home peptides” becomes least useful to me. The relevant safety question changes with the substance, preparation and route.
The risk that interrupts the day
With BPC-157, the greatest problem is how much human safety information is missing. With NAD+ injections, a contamination recall adds a documented manufacturing concern to sparse controlled evidence. For bremelanotide, nausea in the long-term extension was common enough to be a practical part of the result. For topical GHK-Cu, irritation and inconsistent pigment reports complicate the cosmetic appeal.
The comparison loses its value if those differences disappear. None of the four provides a general answer to tiredness, pain, skin ageing and sexual concerns together. The questions page deals with the common points of confusion.